Business UpdateJun 25, 2026, 04:07 PM
Oculis Advances Clinical Programs; Cash Runway into 2H 2029
AI Summary
Oculis Holding AG, a Nasdaq-listed biopharma company, provided an update on its clinical pipeline and financial position. The company reported a strong cash runway extending into the second half of 2029, with no debt and an available CHF100m loan facility. Key clinical programs, Privosegtor and Licaminlimab, are progressing with significant upcoming milestones, including trial initiations and topline results.
Key Highlights
- Current cash runway extends into the second half of 2029.
- Company maintains a strong balance sheet with no debt.
- Privosegtor received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
- PIONEER-2 and PIONEER-3 trials for Privosegtor are set to initiate in 2H 2026.
- PIONEER-1 enrollment for Privosegtor is expected to complete in 2027.
- Licaminlimab's PREDICT-1 trial topline results are anticipated around year-end 2026.
- A CHF100m loan facility is available, not included in the current cash runway.
Price Impact
More from OCS